The U.S. government has given its support to an unfamiliar medication as a potential remedy for autism symptoms despite lacking strong scientific support, according to healthcare professionals. During a White House briefing, Dr. Marty Makary, the head of the U.S. Food and Drug Administration (FDA), declared that leucovorin could benefit “hundreds of thousands” of children with autism.
The FDA has announced that it will classify leucovorin, a type of folate vitamin, as a treatment for individuals with cerebral folate deficiency (CFD), a neurologic disorder. This categorization marks the initial stage in the process of potentially approving leucovorin as a treatment option for certain individuals with autism in the United States.
Folate, a B vitamin present in foods such as leafy greens, legumes, and citrus fruits, is vital for various bodily functions. Folic acid, the synthetic form of folate found in vitamin supplements and fortified grains, is crucial for the normal development of a fetus’s spine, brain, and skull. Medical experts recommend that pregnant women or those attempting to conceive take a daily vitamin supplement containing folic acid to reduce the risk of neural tube defects.
Leucovorin, akin to folic acid, is utilized in Canada by provincial cancer agencies to mitigate the adverse effects of methotrexate, a cancer medication. Methotrexate, an antifolate, disrupts the body’s ability to utilize folic acid necessary for DNA production. Leucovorin is also combined with another cancer drug to treat colon cancer.
The FDA’s approval of leucovorin tablets for individuals with cerebral folate deficiency was based on a review of a limited number of studies indicating a positive impact on verbal communication. Some doctors in the U.S. were already using the drug off-label before this decision.
It is believed that leucovorin may assist certain autistic children who have a receptor hindering folate from reaching the brain. However, the efficacy of leucovorin in treating autism remains uncertain, as autism is primarily considered a genetic condition with potential environmental influences.
Sura Alwan, a birth defects expert at the University of British Columbia, emphasizes that while leucovorin offers hope, its effectiveness is still under investigation. She stresses the importance of transparent communication regarding proven treatments and highlights existing effective supports for autistic individuals.
Research on leucovorin’s impact on autism is ongoing, with studies indicating positive outcomes but requiring further validation in larger populations. It is essential to conduct comprehensive investigations to ascertain the safety and efficacy of leucovorin before considering it as a viable treatment option for autism.
